A carregar...

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

BACKGROUND: Targeted therapy is an important treatment for advanced non-small cell lung cancer (NSCLC) patients with specific genetic mutations, crizotinib can prolong survival in advanced NSCLC patients with echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (EML4-ALK) rear...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Liang, Hongge, Ma, Di, Xu, Yan, Zhao, Jing, Chen, Minjiang, Liu, Xiaoyan, Zhong, Wei, Li, Junling, Wang, Mengzhao
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6733249/
https://ncbi.nlm.nih.gov/pubmed/31564978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S213572
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!